Multitargeted molecular docking study of plant-derived natural products on phosphoinositide-3 kinase pathway components

Medicinal Chemistry Research

Volumn 23, Issue 4, 2014, Pages 1690-1700

  Singh, Pushpendra ^a   Bast, Felix ^a  

^a CENTRAL UNIVERSITY OF PUNJAB   (India)

Author keywords

Cancer; Maestro 9.3; Natural product compounds; Phosphoinositide 3 kinase

Indexed keywords

EMODIN; LUTEOLIN; MORIN; MYRICETIN; NATURAL PRODUCT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; QUERCETIN;

ARTICLE; CELL SURVIVAL; CONFORMATION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HYDROGEN BOND; MOLECULAR DOCKING; PHARMACODYNAMICS; PROTEIN INTERACTION;

EID: 84899432052     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-013-0774-2     Document Type: Article

References (56)

1. Antonarakis ES, Carducci MA, Eisenberger MA (2010) Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 291:1-13. doi:10.1016/j.canlet.2009.08.012
2. Baldo P et al (2008) mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 8:647-665
3. Bartholomeusz C, Gonzalez-Angulo AM (2012) Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 16:121-130. doi:10.1007/s11912-012-0227-y
4. Bolton EE et al (2008) PubChem: integrated platform of small molecules and biological activities. Annu Rep Comput Chem 4:217-241
5. Chen YL, Law P-Y, Loh HH (2005) Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anti-Cancer Agents 5:575-589 (Pubitemid 41601056)
6. Cho JY, Park J (2008) Contribution of natural inhibitors to the understanding of the PI3K/PDK1/PKB pathway in the insulin-mediated intracellular signaling cascade. Int J Mol Sci 9:2217-2230. doi:10.3390/ijms9112217
7. da Rocha AB, Lopes RM, Schwartsmann G (2001) Natural products in anticancer therapy. Curr Opin Pharmacol 1:364-369 (Pubitemid 33585985)
8. Downward J (2008) Targeting RAS and PI3K in lung cancer. Nat Med 14:1315-1316. doi:10.1038/nm1208-1315
9. Drews Jr (2000) Drug discovery: a historical perspective. Science 287:1960-1964
10. Easton J, Houghton P (2006) mTOR and cancer therapy. Oncogene 25:6436-6446 (Pubitemid 44582287)
11. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671-688 (Pubitemid 44151605)
12. Freeman-Cook KD et al (2010) Design of selective, ATP-competitive inhibitors of Akt. J Med Chem 53:4615-4622. doi:10.1021/jm1003842
13. Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749 (Pubitemid 38380917)
14. Friesner RA et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177-6196 (Pubitemid 44595196)
15. Halgren TA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750-1759 (Pubitemid 38380918)
16. Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179-183
17. Hillman GG (2012) Dietary agents in cancer chemoprevention and treatment. J Oncol 2012. doi:10.1155/2012/749310
18. Huang W et al (2012) Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific Protease 1 expression. PLoS ONE 7:e37693. doi:10.1371/journal.pone.0037693
19. Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliver Rev 54:355-366 (Pubitemid 34260958)
20. Jorgensen WL, Tirado-Rives J (1988) The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110:1657-1666
21. Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236. doi:10.1021/ja9621760 (Pubitemid 26399746)
22. Keum Y-S et al (2009) Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm Res 26:2324-2331. doi:10.1007/s11095-009-9948-5
23. Kim HY et al (2012) Raf and PI3K are themolecular targets for the antimetastatic effect of luteolin. Phytother Res. doi:10.1002/ptr.4888
24. Kuo H-M et al (2007) Morin inhibits the growth of human leukemia HL-60 cells via cell cycle arrest and induction of apoptosis through mitochondria dependent pathway. Anticancer Res 27:395-405. doi:10.1002/ptr.4888
25. Lin Y et al (2008) Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr Cancer Drug Targets 8(7):634-646
26. Liu KC et al (2012) The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells. Environ Toxicol. doi:10.1002/tox.21769
27. Lopez-Lazaro M (2009) Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9:31-59
28. LoPiccolo J et al (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11:32. doi:10.1016/j.drup.2007.11.003
29. Lu JJ et al (2004) Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem 47:6104-6107 (Pubitemid 39507351)
30. März AM et al (2013) Large FK506-binding proteins shape the pharmacology of rapamycin. Mol Cell Biol 33:1357-1367. doi:10.1128/MCB.00678-12
31. Morales P, Haza AI (2012) Selective apoptotic effects of piceatannol and myricetin in human cancer cells. J Appl Toxicol 32:986-993. doi:10.1002/jat.1725
32. Morgan TM, Koreckij TD, Corey E (2009) Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9(2):237-249
33. Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797-803 (Pubitemid 41215743)
34. Morphy R (2010) Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 53:1413-1437. doi:10.1021/jm901132v
35. Murphy ST et al (2011) Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1). J Med Chem 54:8490-8500. doi:10.1021/jm201019k
36. Nishimura N et al (2011) Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure†"activity relationships of a series of quinoline and quinoxaline derivatives. J Med Chem 54:4735-4751. doi:10.1021/jm200386s
37. O'Reilly KE et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508 (Pubitemid 43259931)
38. Phosrithong N, Ungwitayatorn J (2010) Molecular docking study on anticancer activity of plant-derived natural products. Med Chem Res 19:817-835. doi:10.1007/s00044-009-9233-5
39. Pratheeshkumar P et al (2012) Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS ONE 7:e47516. doi:10.1371/journal.pone.0047516
40. Rao YK et al (2010) Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells. Chem Res Toxicol 24:238-245. doi:10.1021/tx100318m
41. Roell D, Baniahmad A (2011) The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth Mol. Cell Endocrinol 332:1-8. doi:10.1016/j.mce.2010.09.013
42. Sarkar FH, Li Y (2006) Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66:3347-3350
43. Sarker D et al (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15:4799-4805. doi:10.1158/1078-0432.CCR-08- 0125
44. Shivakumar D et al (2010) Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6:1509-1519. doi:10.1021/ct900587b
45. Singh SV et al (2009) Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res 69:2117-2125. doi:10.1158/0008-5472.CAN-08- 3502
46. Sivaramakrishnan V, Devaraj SN (2010) Morin fosters apoptosis in experimental hepatocellular carcinogenesis model. Chem-Biol Interact 183:284-292. doi:10.1016/j.cbi.2009.11.011
47. Sun F et al (2012) Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 64:599-606. doi:10.1080/01635581.2012.665564
48. Sunil H (2012) Inhibition studies of naturally occurring terpene based compounds with cyclin-dependent kinase 2 enzyme. J Comput Syst Sci doi:10.4172/jcsb.1000092
49. Wang P, Heber D, Henning SM (2012) Quercetin increased the antiproliferative activity of green tea polyphenol (-)-epigallocatechin gallate in prostate cancer cells. Nutr Cancer 64:580-587. doi:10.1080/01635581.2012. 661514
50. Watanabe R, Wei L, Huang J (2011) mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med 52:497-500. doi:10.2967/jnumed. 111.089623
51. Wong K-K, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20:87-90. doi:10.1016/j.gde.2009.11.002
52. Zhang X, et al (2013) Myricetin induces apoptosis in Hepg2 cells through Akt/P70s6 k/bad signaling and mitochondrial apoptotic pathway. Anticancer Agents Med Chem. [Epub ahead of print]
53. Zhang X, Jin B, Huang C (2007) The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets 7:305-316 (Pubitemid 46849235)
54. Zhou H, Luo Y, Huang S (2010) Updates of mTOR inhibitors. Anticancer Agents Med Chem 10(7):571-581
55. Zhou S, Li Y, Hou T (2013) Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors. J Chem Inf Model. doi:10.1021/ci400065e
56. Zhu Q et al (2011) Quercetin induces the apoptosis of human PC-3 cells. Natl J Androl 17(9):790-793